timolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-adrenoreceptor antagonists | 4061 | 26839-75-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
| 20 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 2.74 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 15 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.16 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 61 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.50 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.90 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 17, 1978 | FDA | ATON | |
| March 25, 2020 | PMDA | Senju Pharmaceutical Co., Ltd |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Treatment failure | 749.76 | 13.21 | 495 | 15813 | 137142 | 50451674 |
| Eye irritation | 467.59 | 13.21 | 184 | 16124 | 16956 | 50571860 |
| Intraocular pressure increased | 379.25 | 13.21 | 118 | 16190 | 5398 | 50583418 |
| Ocular hyperaemia | 299.10 | 13.21 | 141 | 16167 | 20151 | 50568665 |
| Eye pain | 265.08 | 13.21 | 145 | 16163 | 28304 | 50560512 |
| Glaucoma | 162.98 | 13.21 | 86 | 16222 | 15600 | 50573216 |
| Eye pruritus | 139.59 | 13.21 | 72 | 16236 | 12462 | 50576354 |
| Vision blurred | 128.47 | 13.21 | 142 | 16166 | 78505 | 50510311 |
| Visual acuity reduced | 117.63 | 13.21 | 76 | 16232 | 20063 | 50568753 |
| Product quality issue | 98.99 | 13.21 | 81 | 16227 | 30777 | 50558039 |
| Product container issue | 95.72 | 13.21 | 30 | 16278 | 1402 | 50587414 |
| Total lung capacity increased | 92.01 | 13.21 | 25 | 16283 | 702 | 50588114 |
| Lacrimation increased | 79.76 | 13.21 | 56 | 16252 | 16936 | 50571880 |
| Choroidal effusion | 78.51 | 13.21 | 20 | 16288 | 434 | 50588382 |
| Bradycardia | 75.03 | 13.21 | 98 | 16210 | 64328 | 50524488 |
| Foreign body sensation in eyes | 73.32 | 13.21 | 26 | 16282 | 1785 | 50587031 |
| Product delivery mechanism issue | 70.00 | 13.21 | 17 | 16291 | 301 | 50588515 |
| Eyelid margin crusting | 69.16 | 13.21 | 20 | 16288 | 708 | 50588108 |
| Frustration tolerance decreased | 67.24 | 13.21 | 34 | 16274 | 5640 | 50583176 |
| Iris adhesions | 64.72 | 13.21 | 16 | 16292 | 306 | 50588510 |
| Cataract | 56.69 | 13.21 | 73 | 16235 | 47227 | 50541589 |
| Corneal oedema | 56.48 | 13.21 | 20 | 16288 | 1367 | 50587449 |
| Ulcerative keratitis | 56.44 | 13.21 | 23 | 16285 | 2310 | 50586506 |
| Choroidal detachment | 56.39 | 13.21 | 13 | 16295 | 182 | 50588634 |
| Eye discharge | 55.79 | 13.21 | 29 | 16279 | 5094 | 50583722 |
| Hypotony of eye | 54.55 | 13.21 | 12 | 16296 | 134 | 50588682 |
| Forced expiratory volume decreased | 54.03 | 13.21 | 27 | 16281 | 4367 | 50584449 |
| Trabeculectomy | 53.16 | 13.21 | 9 | 16299 | 19 | 50588797 |
| Pulmonary thrombosis | 50.38 | 13.21 | 31 | 16277 | 7510 | 50581306 |
| Corneal deposits | 50.38 | 13.21 | 12 | 16296 | 195 | 50588621 |
| Respiration abnormal | 47.45 | 13.21 | 26 | 16282 | 5076 | 50583740 |
| Visual impairment | 46.68 | 13.21 | 81 | 16227 | 68194 | 50520622 |
| Eye inflammation | 46.34 | 13.21 | 24 | 16284 | 4184 | 50584632 |
| Product packaging quantity issue | 45.60 | 13.21 | 16 | 16292 | 1064 | 50587752 |
| Iridocyclitis | 45.50 | 13.21 | 19 | 16289 | 2030 | 50586786 |
| Corneal disorder | 42.68 | 13.21 | 17 | 16291 | 1609 | 50587207 |
| Peak expiratory flow rate decreased | 42.16 | 13.21 | 13 | 16295 | 575 | 50588241 |
| Conjunctival hyperaemia | 41.89 | 13.21 | 18 | 16290 | 2064 | 50586752 |
| Lung diffusion test decreased | 41.71 | 13.21 | 13 | 16295 | 596 | 50588220 |
| Intraocular pressure test abnormal | 38.65 | 13.21 | 9 | 16299 | 132 | 50588684 |
| Punctate keratitis | 38.61 | 13.21 | 12 | 16296 | 545 | 50588271 |
| Retinal disorder | 37.24 | 13.21 | 15 | 16293 | 1462 | 50587354 |
| Ocular discomfort | 36.46 | 13.21 | 19 | 16289 | 3354 | 50585462 |
| Cystoid macular oedema | 34.56 | 13.21 | 14 | 16294 | 1385 | 50587431 |
| Thermal burns of eye | 33.47 | 13.21 | 8 | 16300 | 132 | 50588684 |
| Angle closure glaucoma | 32.62 | 13.21 | 15 | 16293 | 2019 | 50586797 |
| Procollagen type I C-terminal propeptide increased | 32.60 | 13.21 | 6 | 16302 | 24 | 50588792 |
| Abnormal sensation in eye | 32.47 | 13.21 | 14 | 16294 | 1619 | 50587197 |
| Forced vital capacity decreased | 32.45 | 13.21 | 12 | 16296 | 929 | 50587887 |
| Serum procollagen type I N-terminal propeptide increased | 32.40 | 13.21 | 6 | 16302 | 25 | 50588791 |
| Hypersensitivity | 32.23 | 13.21 | 146 | 16162 | 215015 | 50373801 |
| Obstructive airways disorder | 32.19 | 13.21 | 32 | 16276 | 15620 | 50573196 |
| Eye swelling | 32.19 | 13.21 | 36 | 16272 | 20108 | 50568708 |
| Corneal degeneration | 32.00 | 13.21 | 7 | 16301 | 76 | 50588740 |
| Visual field defect | 31.75 | 13.21 | 21 | 16287 | 5758 | 50583058 |
| Incorrect dose administered | 31.22 | 13.21 | 56 | 16252 | 48358 | 50540458 |
| Growth of eyelashes | 31.09 | 13.21 | 8 | 16300 | 181 | 50588635 |
| Liquid product physical issue | 30.78 | 13.21 | 11 | 16297 | 772 | 50588044 |
| Conjunctival ulcer | 30.30 | 13.21 | 6 | 16302 | 38 | 50588778 |
| Abdominal discomfort | 29.75 | 13.21 | 19 | 16289 | 231622 | 50357194 |
| Completed suicide | 29.10 | 13.21 | 4 | 16304 | 131885 | 50456931 |
| Flat anterior chamber of eye | 28.45 | 13.21 | 6 | 16302 | 54 | 50588762 |
| Vitamin B12 decreased | 28.00 | 13.21 | 15 | 16293 | 2800 | 50586016 |
| Blindness | 27.83 | 13.21 | 31 | 16277 | 17238 | 50571578 |
| Pain | 27.71 | 13.21 | 95 | 16213 | 578808 | 50010008 |
| Macular oedema | 26.93 | 13.21 | 16 | 16292 | 3638 | 50585178 |
| Superficial injury of eye | 26.61 | 13.21 | 7 | 16301 | 173 | 50588643 |
| Glaucoma surgery | 26.58 | 13.21 | 6 | 16302 | 76 | 50588740 |
| Chronotropic incompetence | 26.58 | 13.21 | 6 | 16302 | 76 | 50588740 |
| Corneal epithelium defect | 26.55 | 13.21 | 8 | 16300 | 327 | 50588489 |
| Systemic lupus erythematosus | 25.29 | 13.21 | 7 | 16301 | 140615 | 50448201 |
| Atrioventricular block complete | 25.28 | 13.21 | 20 | 16288 | 7235 | 50581581 |
| Hypopyon | 24.80 | 13.21 | 9 | 16299 | 660 | 50588156 |
| Erythema of eyelid | 24.73 | 13.21 | 12 | 16296 | 1821 | 50586995 |
| Synovitis | 24.57 | 13.21 | 5 | 16303 | 123860 | 50464956 |
| Retinal detachment | 24.28 | 13.21 | 17 | 16291 | 5112 | 50583704 |
| Dry mouth | 24.26 | 13.21 | 55 | 16253 | 56123 | 50532693 |
| Keratopathy | 23.92 | 13.21 | 8 | 16300 | 460 | 50588356 |
| Toxic anterior segment syndrome | 23.41 | 13.21 | 11 | 16297 | 1554 | 50587262 |
| Vitreous haemorrhage | 22.26 | 13.21 | 11 | 16297 | 1737 | 50587079 |
| Glossodynia | 22.24 | 13.21 | 5 | 16303 | 115564 | 50473252 |
| Vitreous floaters | 21.47 | 13.21 | 16 | 16292 | 5298 | 50583518 |
| Eyelid irritation | 21.43 | 13.21 | 7 | 16301 | 374 | 50588442 |
| Fall | 21.20 | 13.21 | 182 | 16126 | 334750 | 50254066 |
| Corneal thickening | 20.84 | 13.21 | 4 | 16304 | 21 | 50588795 |
| Conjunctivitis allergic | 20.58 | 13.21 | 8 | 16300 | 710 | 50588106 |
| Haemangioma congenital | 20.45 | 13.21 | 7 | 16301 | 432 | 50588384 |
| Intraocular pressure fluctuation | 20.39 | 13.21 | 4 | 16304 | 24 | 50588792 |
| Blood pressure systolic increased | 20.33 | 13.21 | 39 | 16269 | 35410 | 50553406 |
| Arthralgia | 20.27 | 13.21 | 73 | 16235 | 438629 | 50150187 |
| Open angle glaucoma | 19.97 | 13.21 | 6 | 16302 | 243 | 50588573 |
| Product physical consistency issue | 19.96 | 13.21 | 7 | 16301 | 465 | 50588351 |
| Blindness unilateral | 19.47 | 13.21 | 15 | 16293 | 5220 | 50583596 |
| Foreign body in eye | 19.39 | 13.21 | 5 | 16303 | 114 | 50588702 |
| Dry eye | 19.26 | 13.21 | 36 | 16272 | 32059 | 50556757 |
| Optic nerve cupping | 19.04 | 13.21 | 3 | 16305 | 3 | 50588813 |
| Infusion related reaction | 19.04 | 13.21 | 16 | 16292 | 169541 | 50419275 |
| Eye disorder | 18.01 | 13.21 | 26 | 16282 | 18713 | 50570103 |
| Conjunctivitis | 17.91 | 13.21 | 24 | 16284 | 16121 | 50572695 |
| Achromotrichia acquired | 17.83 | 13.21 | 3 | 16305 | 6 | 50588810 |
| Keratitis interstitial | 17.83 | 13.21 | 3 | 16305 | 6 | 50588810 |
| Bronchopulmonary disease | 17.83 | 13.21 | 3 | 16305 | 6 | 50588810 |
| Drug intolerance | 17.71 | 13.21 | 27 | 16281 | 219077 | 50369739 |
| Wound | 17.69 | 13.21 | 6 | 16302 | 105788 | 50483028 |
| Hypotonia | 17.41 | 13.21 | 17 | 16291 | 8117 | 50580699 |
| Joint swelling | 17.29 | 13.21 | 33 | 16275 | 245253 | 50343563 |
| Eye allergy | 17.07 | 13.21 | 7 | 16301 | 714 | 50588102 |
| Symblepharon | 16.91 | 13.21 | 4 | 16304 | 63 | 50588753 |
| Sinus bradycardia | 16.82 | 13.21 | 21 | 16287 | 13162 | 50575654 |
| Contraindicated product administered | 16.79 | 13.21 | 14 | 16294 | 148944 | 50439872 |
| Hypothermia | 16.72 | 13.21 | 20 | 16288 | 11996 | 50576820 |
| Eye injury | 16.56 | 13.21 | 8 | 16300 | 1202 | 50587614 |
| Corneal endothelial cell loss | 16.10 | 13.21 | 3 | 16305 | 13 | 50588803 |
| Haemangioma | 16.07 | 13.21 | 10 | 16298 | 2470 | 50586346 |
| Conjunctival follicles | 15.92 | 13.21 | 3 | 16305 | 14 | 50588802 |
| Eye oedema | 15.77 | 13.21 | 8 | 16300 | 1335 | 50587481 |
| Product use issue | 15.70 | 13.21 | 15 | 16293 | 149460 | 50439356 |
| Abdominal pain | 15.60 | 13.21 | 33 | 16275 | 236195 | 50352621 |
| Uveitis | 15.49 | 13.21 | 17 | 16291 | 9293 | 50579523 |
| Intraocular lens implant | 15.36 | 13.21 | 5 | 16303 | 264 | 50588552 |
| Pyrexia | 15.18 | 13.21 | 67 | 16241 | 380136 | 50208680 |
| Swelling | 15.06 | 13.21 | 26 | 16282 | 200846 | 50387970 |
| Product dose omission issue | 14.98 | 13.21 | 106 | 16202 | 183732 | 50405084 |
| Intraocular pressure decreased | 14.76 | 13.21 | 4 | 16304 | 111 | 50588705 |
| Lethargy | 14.67 | 13.21 | 42 | 16266 | 49390 | 50539426 |
| Hepatic enzyme increased | 14.18 | 13.21 | 14 | 16294 | 137366 | 50451450 |
| Febrile neutropenia | 13.97 | 13.21 | 7 | 16301 | 97660 | 50491156 |
| Ocular pemphigoid | 13.94 | 13.21 | 3 | 16305 | 30 | 50588786 |
| Vitrectomy | 13.90 | 13.21 | 4 | 16304 | 139 | 50588677 |
| Confusional state | 13.89 | 13.21 | 105 | 16203 | 185823 | 50402993 |
| Iris neovascularisation | 13.76 | 13.21 | 3 | 16305 | 32 | 50588784 |
| Retinal vascular occlusion | 13.70 | 13.21 | 5 | 16303 | 373 | 50588443 |
| Subretinal fluid | 13.68 | 13.21 | 5 | 16303 | 374 | 50588442 |
| Stag horn calculus | 13.66 | 13.21 | 4 | 16304 | 148 | 50588668 |
| Retinal degeneration | 13.58 | 13.21 | 6 | 16302 | 735 | 50588081 |
| Maternal exposure during pregnancy | 13.58 | 13.21 | 19 | 16289 | 159759 | 50429057 |
| No adverse event | 13.53 | 13.21 | 32 | 16276 | 33546 | 50555270 |
| Vertigo | 13.45 | 13.21 | 42 | 16266 | 51790 | 50537026 |
| Iritis | 13.44 | 13.21 | 9 | 16299 | 2519 | 50586297 |
| Photophobia | 13.36 | 13.21 | 20 | 16288 | 14867 | 50573949 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Treatment failure | 774.67 | 14.63 | 344 | 10918 | 36595 | 29526670 |
| Intraocular pressure increased | 355.67 | 14.63 | 113 | 11149 | 4676 | 29558589 |
| Eye irritation | 286.09 | 14.63 | 101 | 11161 | 5797 | 29557468 |
| Eye pain | 165.19 | 14.63 | 83 | 11179 | 11512 | 29551753 |
| Visual acuity reduced | 162.11 | 14.63 | 89 | 11173 | 14787 | 29548478 |
| Ocular hyperaemia | 140.86 | 14.63 | 69 | 11193 | 9058 | 29554207 |
| Vision blurred | 107.15 | 14.63 | 102 | 11160 | 40074 | 29523191 |
| Glaucoma | 83.59 | 14.63 | 42 | 11220 | 5815 | 29557450 |
| Corneal deposits | 80.83 | 14.63 | 18 | 11244 | 178 | 29563087 |
| Corneal oedema | 76.75 | 14.63 | 25 | 11237 | 1117 | 29562148 |
| Product delivery mechanism issue | 75.22 | 14.63 | 16 | 11246 | 125 | 29563140 |
| Lacrimation increased | 68.47 | 14.63 | 39 | 11223 | 6941 | 29556324 |
| Bradycardia | 66.71 | 14.63 | 102 | 11160 | 65527 | 29497738 |
| Product quality issue | 63.84 | 14.63 | 51 | 11211 | 15844 | 29547421 |
| Intraocular pressure test abnormal | 60.05 | 14.63 | 12 | 11250 | 66 | 29563199 |
| Eye pruritus | 58.71 | 14.63 | 30 | 11232 | 4302 | 29558963 |
| Product container issue | 56.59 | 14.63 | 17 | 11245 | 580 | 29562685 |
| Anterior chamber disorder | 49.02 | 14.63 | 10 | 11252 | 62 | 29563203 |
| Cataract | 48.85 | 14.63 | 51 | 11211 | 22327 | 29540938 |
| Blindness | 47.05 | 14.63 | 38 | 11224 | 11985 | 29551280 |
| Hyphaema | 46.70 | 14.63 | 14 | 11248 | 474 | 29562791 |
| Toxic anterior segment syndrome | 43.65 | 14.63 | 16 | 11246 | 1020 | 29562245 |
| Eye discharge | 42.76 | 14.63 | 18 | 11244 | 1658 | 29561607 |
| Choroidal detachment | 37.17 | 14.63 | 11 | 11251 | 356 | 29562909 |
| Foreign body sensation in eyes | 36.73 | 14.63 | 12 | 11250 | 541 | 29562724 |
| Corneal disorder | 35.84 | 14.63 | 13 | 11249 | 804 | 29562461 |
| Dry eye | 34.95 | 14.63 | 26 | 11236 | 7270 | 29555995 |
| Erythema of eyelid | 34.33 | 14.63 | 12 | 11250 | 666 | 29562599 |
| Ocular discomfort | 32.89 | 14.63 | 15 | 11247 | 1674 | 29561591 |
| Visual impairment | 32.75 | 14.63 | 48 | 11214 | 29660 | 29533605 |
| Floppy iris syndrome | 30.21 | 14.63 | 9 | 11253 | 298 | 29562967 |
| Ocular hypertension | 29.86 | 14.63 | 11 | 11251 | 711 | 29562554 |
| Blindness unilateral | 28.95 | 14.63 | 18 | 11244 | 3756 | 29559509 |
| Iridocyclitis | 28.71 | 14.63 | 13 | 11249 | 1427 | 29561838 |
| Visual acuity tests abnormal | 28.08 | 14.63 | 6 | 11256 | 48 | 29563217 |
| Eyelid irritation | 26.53 | 14.63 | 6 | 11256 | 64 | 29563201 |
| Scleral hyperaemia | 26.44 | 14.63 | 6 | 11256 | 65 | 29563200 |
| Ulcerative keratitis | 25.72 | 14.63 | 12 | 11250 | 1411 | 29561854 |
| Eye infection | 25.33 | 14.63 | 15 | 11247 | 2868 | 29560397 |
| Off label use | 24.99 | 14.63 | 48 | 11214 | 300752 | 29262513 |
| Eye swelling | 24.99 | 14.63 | 23 | 11239 | 8634 | 29554631 |
| Completed suicide | 24.09 | 14.63 | 3 | 11259 | 90243 | 29473022 |
| Eyelid oedema | 23.28 | 14.63 | 17 | 11245 | 4619 | 29558646 |
| Conjunctival oedema | 23.15 | 14.63 | 8 | 11254 | 429 | 29562836 |
| Eye disorder | 22.98 | 14.63 | 21 | 11241 | 7813 | 29555452 |
| Product packaging quantity issue | 22.17 | 14.63 | 9 | 11253 | 756 | 29562509 |
| Uveitis | 21.59 | 14.63 | 18 | 11244 | 5929 | 29557336 |
| Atrioventricular block second degree | 21.53 | 14.63 | 14 | 11248 | 3154 | 29560111 |
| Intraocular pressure decreased | 21.42 | 14.63 | 5 | 11257 | 62 | 29563203 |
| Growth of eyelashes | 21.42 | 14.63 | 5 | 11257 | 62 | 29563203 |
| Retinal detachment | 20.89 | 14.63 | 16 | 11246 | 4670 | 29558595 |
| Trabeculectomy | 20.68 | 14.63 | 4 | 11258 | 18 | 29563247 |
| Scleral disorder | 20.17 | 14.63 | 4 | 11258 | 21 | 29563244 |
| Blepharitis | 19.51 | 14.63 | 9 | 11253 | 1031 | 29562234 |
| Hypotony of eye | 19.28 | 14.63 | 5 | 11257 | 98 | 29563167 |
| Accidental exposure to product | 19.10 | 14.63 | 22 | 11240 | 10731 | 29552534 |
| Eyelids pruritus | 19.05 | 14.63 | 5 | 11257 | 103 | 29563162 |
| Anterior chamber inflammation | 19.01 | 14.63 | 6 | 11256 | 242 | 29563023 |
| Corneal degeneration | 18.72 | 14.63 | 4 | 11258 | 32 | 29563233 |
| Cataract nuclear | 18.65 | 14.63 | 7 | 11255 | 477 | 29562788 |
| Conjunctival hyperaemia | 18.42 | 14.63 | 11 | 11251 | 2134 | 29561131 |
| Visual field defect | 18.23 | 14.63 | 14 | 11248 | 4102 | 29559163 |
| Eye inflammation | 18.05 | 14.63 | 10 | 11252 | 1686 | 29561579 |
| Dizziness | 17.61 | 14.63 | 128 | 11134 | 189556 | 29373709 |
| Optic nerve cupping | 17.57 | 14.63 | 4 | 11258 | 44 | 29563221 |
| Administration site discomfort | 17.49 | 14.63 | 4 | 11258 | 45 | 29563220 |
| Dermatitis | 17.42 | 14.63 | 18 | 11244 | 7780 | 29555485 |
| Eye haemorrhage | 17.19 | 14.63 | 13 | 11249 | 3723 | 29559542 |
| Macular degeneration | 17.19 | 14.63 | 10 | 11252 | 1850 | 29561415 |
| Punctate keratitis | 17.15 | 14.63 | 6 | 11256 | 334 | 29562931 |
| Liquid product physical issue | 17.06 | 14.63 | 6 | 11256 | 339 | 29562926 |
| Cardiovascular insufficiency | 17.02 | 14.63 | 9 | 11253 | 1384 | 29561881 |
| Eyelid margin crusting | 16.92 | 14.63 | 5 | 11257 | 161 | 29563104 |
| Corneal epithelium defect | 16.75 | 14.63 | 6 | 11256 | 358 | 29562907 |
| Funguria | 16.68 | 14.63 | 4 | 11258 | 56 | 29563209 |
| Abnormal sensation in eye | 16.67 | 14.63 | 7 | 11255 | 641 | 29562624 |
| Hypersensitivity | 16.56 | 14.63 | 51 | 11211 | 52852 | 29510413 |
| Electrolyte depletion | 16.49 | 14.63 | 5 | 11257 | 176 | 29563089 |
| Coronavirus infection | 16.38 | 14.63 | 12 | 11250 | 3276 | 29559989 |
| Madarosis | 15.81 | 14.63 | 5 | 11257 | 203 | 29563062 |
| Corneal infection | 15.80 | 14.63 | 3 | 11259 | 12 | 29563253 |
| Ectropion | 15.80 | 14.63 | 4 | 11258 | 71 | 29563194 |
| Photophobia | 15.53 | 14.63 | 15 | 11247 | 5980 | 29557285 |
| Intraocular pressure fluctuation | 15.25 | 14.63 | 3 | 11259 | 15 | 29563250 |
| Retinal haemorrhage | 15.05 | 14.63 | 13 | 11249 | 4491 | 29558774 |
| Cutis laxa | 14.94 | 14.63 | 4 | 11258 | 89 | 29563176 |
| Sinus bradycardia | 14.63 | 14.63 | 20 | 11242 | 11583 | 29551682 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Intraocular pressure increased | 505.02 | 12.16 | 161 | 20227 | 8141 | 64470203 |
| Eye irritation | 338.32 | 12.16 | 142 | 20246 | 15714 | 64462630 |
| Eye pain | 219.00 | 12.16 | 132 | 20256 | 31493 | 64446851 |
| Visual acuity reduced | 218.78 | 12.16 | 125 | 20263 | 27016 | 64451328 |
| Ocular hyperaemia | 214.94 | 12.16 | 116 | 20272 | 22448 | 64455896 |
| Vision blurred | 153.47 | 12.16 | 165 | 20223 | 90151 | 64388193 |
| Glaucoma | 144.48 | 12.16 | 80 | 20308 | 16268 | 64462076 |
| Bradycardia | 133.03 | 12.16 | 175 | 20213 | 118044 | 64360300 |
| Eye pruritus | 106.54 | 12.16 | 60 | 20328 | 12599 | 64465745 |
| Lacrimation increased | 102.84 | 12.16 | 67 | 20321 | 18279 | 64460065 |
| Corneal oedema | 100.72 | 12.16 | 35 | 20353 | 2308 | 64476036 |
| Total lung capacity increased | 93.14 | 12.16 | 25 | 20363 | 683 | 64477661 |
| Choroidal detachment | 89.88 | 12.16 | 23 | 20365 | 519 | 64477825 |
| Corneal deposits | 87.74 | 12.16 | 21 | 20367 | 356 | 64477988 |
| Eye discharge | 74.47 | 12.16 | 35 | 20353 | 5049 | 64473295 |
| Corneal disorder | 70.94 | 12.16 | 26 | 20362 | 2001 | 64476343 |
| Iris adhesions | 70.89 | 12.16 | 19 | 20369 | 516 | 64477828 |
| Choroidal effusion | 68.36 | 12.16 | 19 | 20369 | 593 | 64477751 |
| Intraocular pressure test abnormal | 67.26 | 12.16 | 14 | 20374 | 120 | 64478224 |
| Cataract | 62.45 | 12.16 | 79 | 20309 | 51183 | 64427161 |
| Ulcerative keratitis | 60.26 | 12.16 | 26 | 20362 | 3071 | 64475273 |
| Trabeculectomy | 60.17 | 12.16 | 11 | 20377 | 43 | 64478301 |
| Toxic anterior segment syndrome | 59.30 | 12.16 | 24 | 20364 | 2415 | 64475929 |
| Frustration tolerance decreased | 54.17 | 12.16 | 30 | 20358 | 6095 | 64472249 |
| Hypotony of eye | 49.15 | 12.16 | 12 | 20376 | 222 | 64478122 |
| Visual field defect | 48.73 | 12.16 | 31 | 20357 | 8115 | 64470229 |
| Conjunctival hyperaemia | 48.50 | 12.16 | 24 | 20364 | 3875 | 64474469 |
| Completed suicide | 47.83 | 12.16 | 7 | 20381 | 224407 | 64253937 |
| Eye inflammation | 46.30 | 12.16 | 25 | 20363 | 4832 | 64473512 |
| Blindness | 45.99 | 12.16 | 45 | 20343 | 21974 | 64456370 |
| Foreign body sensation in eyes | 45.26 | 12.16 | 18 | 20370 | 1731 | 64476613 |
| Hyphaema | 45.21 | 12.16 | 14 | 20374 | 641 | 64477703 |
| Iridocyclitis | 44.71 | 12.16 | 21 | 20367 | 3024 | 64475320 |
| Floppy iris syndrome | 44.52 | 12.16 | 12 | 20376 | 333 | 64478011 |
| Anterior chamber disorder | 43.90 | 12.16 | 10 | 20378 | 135 | 64478209 |
| Forced expiratory volume decreased | 43.25 | 12.16 | 27 | 20361 | 6840 | 64471504 |
| Respiration abnormal | 42.75 | 12.16 | 26 | 20362 | 6289 | 64472055 |
| Peak expiratory flow rate decreased | 41.57 | 12.16 | 13 | 20375 | 615 | 64477729 |
| Corneal epithelium defect | 40.46 | 12.16 | 13 | 20375 | 672 | 64477672 |
| Corneal degeneration | 39.62 | 12.16 | 9 | 20379 | 120 | 64478224 |
| Pulmonary thrombosis | 39.34 | 12.16 | 30 | 20358 | 10488 | 64467856 |
| Ocular discomfort | 39.29 | 12.16 | 21 | 20367 | 3978 | 64474366 |
| Punctate keratitis | 37.48 | 12.16 | 13 | 20375 | 852 | 64477492 |
| Retinal detachment | 37.20 | 12.16 | 26 | 20362 | 7950 | 64470394 |
| Erythema of eyelid | 36.58 | 12.16 | 16 | 20372 | 1952 | 64476392 |
| Uveitis | 36.38 | 12.16 | 31 | 20357 | 12677 | 64465667 |
| Angle closure glaucoma | 34.98 | 12.16 | 17 | 20371 | 2640 | 64475704 |
| Cystoid macular oedema | 34.86 | 12.16 | 15 | 20373 | 1759 | 64476585 |
| Lung diffusion test decreased | 33.37 | 12.16 | 13 | 20375 | 1183 | 64477161 |
| Product quality issue | 33.27 | 12.16 | 44 | 20344 | 29755 | 64448589 |
| Procollagen type I C-terminal propeptide increased | 32.71 | 12.16 | 6 | 20382 | 24 | 64478320 |
| Ocular hypertension | 32.70 | 12.16 | 13 | 20375 | 1248 | 64477096 |
| Serum procollagen type I N-terminal propeptide increased | 31.96 | 12.16 | 6 | 20382 | 28 | 64478316 |
| Eyelid margin crusting | 31.92 | 12.16 | 11 | 20377 | 707 | 64477637 |
| Sinus bradycardia | 30.63 | 12.16 | 37 | 20351 | 22856 | 64455488 |
| Forced vital capacity decreased | 30.39 | 12.16 | 13 | 20375 | 1503 | 64476841 |
| Intraocular pressure fluctuation | 30.02 | 12.16 | 6 | 20382 | 41 | 64478303 |
| Flat anterior chamber of eye | 27.61 | 12.16 | 7 | 20381 | 152 | 64478192 |
| Atrioventricular block complete | 27.40 | 12.16 | 28 | 20360 | 14390 | 64463954 |
| Vitreous haemorrhage | 26.98 | 12.16 | 15 | 20373 | 3070 | 64475274 |
| Fall | 26.84 | 12.16 | 224 | 20164 | 416602 | 64061742 |
| Blepharitis | 26.75 | 12.16 | 14 | 20374 | 2541 | 64475803 |
| Endophthalmitis | 26.22 | 12.16 | 18 | 20370 | 5347 | 64472997 |
| Vitamin B12 decreased | 25.95 | 12.16 | 14 | 20374 | 2701 | 64475643 |
| Chronotropic incompetence | 25.75 | 12.16 | 6 | 20382 | 90 | 64478254 |
| Product container issue | 25.55 | 12.16 | 10 | 20378 | 921 | 64477423 |
| Retinal disorder | 25.18 | 12.16 | 12 | 20376 | 1784 | 64476560 |
| Blindness unilateral | 24.66 | 12.16 | 19 | 20369 | 6742 | 64471602 |
| Conjunctivitis allergic | 24.58 | 12.16 | 10 | 20378 | 1020 | 64477324 |
| Eye disorder | 24.44 | 12.16 | 30 | 20358 | 18839 | 64459505 |
| Visual acuity tests abnormal | 24.32 | 12.16 | 6 | 20382 | 116 | 64478228 |
| Conjunctival oedema | 24.26 | 12.16 | 10 | 20378 | 1054 | 64477290 |
| Atrioventricular block | 24.05 | 12.16 | 24 | 20364 | 11991 | 64466353 |
| Visual impairment | 23.81 | 12.16 | 64 | 20324 | 74013 | 64404331 |
| Keratopathy | 23.63 | 12.16 | 9 | 20379 | 771 | 64477573 |
| Abdominal pain | 23.60 | 12.16 | 39 | 20349 | 312336 | 64166008 |
| Growth of eyelashes | 23.38 | 12.16 | 6 | 20382 | 137 | 64478207 |
| Optic nerve cupping | 23.24 | 12.16 | 5 | 20383 | 51 | 64478293 |
| Product delivery mechanism issue | 23.13 | 12.16 | 6 | 20382 | 143 | 64478201 |
| Dizziness | 22.98 | 12.16 | 222 | 20166 | 429941 | 64048403 |
| Abnormal sensation in eye | 22.58 | 12.16 | 11 | 20377 | 1716 | 64476628 |
| Ectropion | 21.91 | 12.16 | 7 | 20381 | 355 | 64477989 |
| Corneal thickening | 21.81 | 12.16 | 4 | 20384 | 16 | 64478328 |
| Thermal burns of eye | 21.28 | 12.16 | 5 | 20383 | 78 | 64478266 |
| Hypopyon | 21.21 | 12.16 | 9 | 20379 | 1020 | 64477324 |
| Atrioventricular block second degree | 21.09 | 12.16 | 17 | 20371 | 6437 | 64471907 |
| Glaucoma surgery | 20.93 | 12.16 | 5 | 20383 | 84 | 64478260 |
| Vertigo | 19.99 | 12.16 | 52 | 20336 | 58959 | 64419385 |
| Hypotonia | 19.92 | 12.16 | 21 | 20367 | 11191 | 64467153 |
| Anterior chamber inflammation | 19.68 | 12.16 | 7 | 20381 | 494 | 64477850 |
| Obstructive airways disorder | 19.62 | 12.16 | 30 | 20358 | 23155 | 64455189 |
| Synovitis | 19.11 | 12.16 | 4 | 20384 | 99086 | 64379258 |
| Iritis | 18.99 | 12.16 | 12 | 20376 | 3104 | 64475240 |
| Corneal opacity | 18.94 | 12.16 | 8 | 20380 | 897 | 64477447 |
| Off label use | 18.87 | 12.16 | 120 | 20268 | 632686 | 63845658 |
| Eyelid irritation | 18.86 | 12.16 | 6 | 20382 | 300 | 64478044 |
| Corneal decompensation | 18.57 | 12.16 | 4 | 20384 | 41 | 64478303 |
| Dry eye | 18.44 | 12.16 | 33 | 20355 | 28986 | 64449358 |
| Dry mouth | 18.22 | 12.16 | 51 | 20337 | 60367 | 64417977 |
| Confusional state | 18.21 | 12.16 | 143 | 20245 | 261001 | 64217343 |
| Conjunctivitis | 18.17 | 12.16 | 27 | 20361 | 20327 | 64458017 |
| Toxicity to various agents | 18.03 | 12.16 | 57 | 20331 | 363456 | 64114888 |
| Symblepharon | 17.47 | 12.16 | 5 | 20383 | 174 | 64478170 |
| Vitreal cells | 17.43 | 12.16 | 4 | 20384 | 56 | 64478288 |
| Corneal endothelial cell loss | 17.28 | 12.16 | 3 | 20385 | 8 | 64478336 |
| Macular fibrosis | 17.27 | 12.16 | 7 | 20381 | 707 | 64477637 |
| Blood pressure systolic increased | 17.19 | 12.16 | 44 | 20344 | 49409 | 64428935 |
| Instillation site irritation | 17.17 | 12.16 | 4 | 20384 | 60 | 64478284 |
| Photophobia | 16.98 | 12.16 | 24 | 20364 | 17269 | 64461075 |
| Hyponatraemia | 16.95 | 12.16 | 92 | 20296 | 148247 | 64330097 |
| Corneal infection | 16.87 | 12.16 | 4 | 20384 | 65 | 64478279 |
| Arthralgia | 16.38 | 12.16 | 78 | 20310 | 442182 | 64036162 |
| Eye swelling | 16.34 | 12.16 | 27 | 20361 | 22254 | 64456090 |
| Macular oedema | 16.29 | 12.16 | 13 | 20375 | 4854 | 64473490 |
| Dermatitis | 16.21 | 12.16 | 24 | 20364 | 18005 | 64460339 |
| Liquid product physical issue | 16.15 | 12.16 | 7 | 20381 | 835 | 64477509 |
| Bronchopulmonary disease | 15.98 | 12.16 | 3 | 20385 | 14 | 64478330 |
| Corneal pigmentation | 15.98 | 12.16 | 3 | 20385 | 14 | 64478330 |
| Heterochromia iridis | 15.65 | 12.16 | 3 | 20385 | 16 | 64478328 |
| Keratitis interstitial | 15.65 | 12.16 | 3 | 20385 | 16 | 64478328 |
| Achromotrichia acquired | 15.65 | 12.16 | 3 | 20385 | 16 | 64478328 |
| Product complaint | 15.47 | 12.16 | 19 | 20369 | 11935 | 64466409 |
| Pain | 15.46 | 12.16 | 107 | 20281 | 553404 | 63924940 |
| Eyelid ptosis | 15.44 | 12.16 | 17 | 20371 | 9508 | 64468836 |
| Corneal scar | 15.38 | 12.16 | 5 | 20383 | 268 | 64478076 |
| Conjunctival follicles | 15.35 | 12.16 | 3 | 20385 | 18 | 64478326 |
| Arrhythmia | 15.29 | 12.16 | 44 | 20344 | 52900 | 64425444 |
| Systemic lupus erythematosus | 15.24 | 12.16 | 3 | 20385 | 77609 | 64400735 |
| Scleral hyperaemia | 15.23 | 12.16 | 5 | 20383 | 277 | 64478067 |
| Retinal haemorrhage | 15.22 | 12.16 | 15 | 20373 | 7383 | 64470961 |
| Vitreous floaters | 15.16 | 12.16 | 14 | 20374 | 6359 | 64471985 |
| Loss of consciousness | 14.96 | 12.16 | 89 | 20299 | 148276 | 64330068 |
| Oversensing | 14.95 | 12.16 | 3 | 20385 | 21 | 64478323 |
| Therapeutic product effect incomplete | 14.93 | 12.16 | 7 | 20381 | 103475 | 64374869 |
| Infusion related reaction | 14.93 | 12.16 | 18 | 20370 | 164449 | 64313895 |
| Nodal rhythm | 14.90 | 12.16 | 10 | 20378 | 2864 | 64475480 |
| Abdominal discomfort | 14.48 | 12.16 | 22 | 20366 | 182300 | 64296044 |
| Multiple organ dysfunction syndrome | 14.42 | 12.16 | 7 | 20381 | 101406 | 64376938 |
| Product use issue | 14.42 | 12.16 | 16 | 20372 | 151699 | 64326645 |
| Administration site discomfort | 14.39 | 12.16 | 4 | 20384 | 125 | 64478219 |
| Superficial injury of eye | 14.39 | 12.16 | 4 | 20384 | 125 | 64478219 |
| Subretinal fluid | 14.34 | 12.16 | 6 | 20382 | 657 | 64477687 |
| Electrolyte depletion | 14.18 | 12.16 | 5 | 20383 | 344 | 64478000 |
| Metamorphopsia | 14.17 | 12.16 | 7 | 20381 | 1125 | 64477219 |
| Iris transillumination defect | 14.12 | 12.16 | 4 | 20384 | 134 | 64478210 |
| Eye oedema | 13.83 | 12.16 | 8 | 20380 | 1765 | 64476579 |
| Chorioretinal disorder | 13.71 | 12.16 | 4 | 20384 | 149 | 64478195 |
| Drug intolerance | 13.70 | 12.16 | 24 | 20364 | 187968 | 64290376 |
| Eyelid oedema | 13.50 | 12.16 | 18 | 20370 | 12261 | 64466083 |
| Corneal thinning | 13.44 | 12.16 | 4 | 20384 | 160 | 64478184 |
| Intraocular pressure decreased | 13.34 | 12.16 | 4 | 20384 | 164 | 64478180 |
| Cardiovascular insufficiency | 13.29 | 12.16 | 9 | 20379 | 2615 | 64475729 |
| Stag horn calculus | 13.16 | 12.16 | 4 | 20384 | 172 | 64478172 |
| Hepatic enzyme increased | 13.14 | 12.16 | 13 | 20375 | 129930 | 64348414 |
| Maternal exposure during pregnancy | 13.06 | 12.16 | 7 | 20381 | 95877 | 64382467 |
| Coronavirus infection | 12.87 | 12.16 | 12 | 20376 | 5518 | 64472826 |
| Alkalosis hypochloraemic | 12.83 | 12.16 | 5 | 20383 | 455 | 64477889 |
| Pyrexia | 12.80 | 12.16 | 114 | 20274 | 558530 | 63919814 |
| Seborrhoeic keratosis | 12.79 | 12.16 | 8 | 20380 | 2032 | 64476312 |
| Extrasystoles | 12.78 | 12.16 | 13 | 20375 | 6645 | 64471699 |
| Scleral disorder | 12.75 | 12.16 | 4 | 20384 | 191 | 64478153 |
| Cataract subcapsular | 12.65 | 12.16 | 6 | 20382 | 883 | 64477461 |
| Eyelid disorder | 12.63 | 12.16 | 7 | 20381 | 1424 | 64476920 |
| Macular degeneration | 12.54 | 12.16 | 12 | 20376 | 5698 | 64472646 |
| Cataract operation | 12.38 | 12.16 | 10 | 20378 | 3796 | 64474548 |
| Product substitution issue | 12.24 | 12.16 | 21 | 20367 | 17840 | 64460504 |
| Retinal vascular occlusion | 12.20 | 12.16 | 5 | 20383 | 519 | 64477825 |
| Corneal lesion | 12.16 | 12.16 | 3 | 20385 | 58 | 64478286 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C07AA06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, non-selective |
| ATC | C07BA06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, non-selective, and thiazides |
| ATC | C07DA06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS Beta blocking agents, non-selective, thiazides and other diuretics |
| ATC | S01ED01 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
| ATC | S01ED51 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D000319 | Adrenergic beta-Antagonists |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:38070 | antiarrhythmic agent |
| CHEBI has role | CHEBI:39456 | antiglaucoma agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Myocardial Reinfarction Prevention | indication | ||
| Migraine Prevention | indication | ||
| Malignant glaucoma | off-label use | 10100008 | |
| Aphakic glaucoma | off-label use | 15374009 | |
| Secondary glaucoma | off-label use | 95717004 | |
| Angina pectoris | off-label use | 194828000 | |
| Angle-closure glaucoma | off-label use | 392291006 | DOID:13550 |
| Mitral valve prolapse | off-label use | 409712001 | |
| Stalled wound | off-label use | 789507005 | |
| Anuria | contraindication | 2472002 | DOID:2983 |
| Bronchospasm | contraindication | 4386001 | |
| Hypercholesterolemia | contraindication | 13644009 | |
| Secondary angle-closure glaucoma | contraindication | 21571006 | |
| Complete atrioventricular block | contraindication | 27885002 | |
| Hypovolemia | contraindication | 28560003 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Acute cerebrovascular insufficiency | contraindication | 29322000 | |
| Dehydration | contraindication | 34095006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Hyperuricemia | contraindication | 35885006 | DOID:1920 |
| Anaphylaxis | contraindication | 39579001 | |
| Hypokalemia | contraindication | 43339004 | |
| Sinus bradycardia | contraindication | 49710005 | |
| General anesthesia | contraindication | 50697003 | |
| Thromboangiitis obliterans | contraindication | 52403007 | DOID:12918 |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Sympathectomy | contraindication | 57071006 | |
| Acute nephropathy | contraindication | 58574008 | |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Hypochloremic alkalosis | contraindication | 70134007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Cardiogenic shock | contraindication | 89138009 | |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Partial atrioventricular block | contraindication | 195039008 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Raynaud's phenomenon | contraindication | 266261006 | |
| Neonatal hyperbilirubinemia | contraindication | 281610001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
| Right ventricular failure | contraindication | 367363000 | |
| Azotemia | contraindication | 445009001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.15 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 7030149 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 7320976 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 7642258 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 8133890 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 8354409 | April 19, 2022 | REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 8748425 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 9474751 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 9770453 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 9907801 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID |
| 0.2%;EQ 0.5% BASE | COMBIGAN | ALLERGAN | N021398 | Oct. 30, 2007 | RX | SOLUTION/DROPS | OPHTHALMIC | 9907802 | April 19, 2022 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.25% BASE | TIMOLOL MALEATE | AMRING PHARMS | A212592 | Dec. 13, 2021 | RX | SOLUTION/DROPS | OPHTHALMIC | Aug. 25, 2022 | COMPETITIVE GENERIC THERAPY |
| EQ 0.5% BASE | TIMOLOL MALEATE | AMRING PHARMS | A212592 | Dec. 13, 2021 | RX | SOLUTION/DROPS | OPHTHALMIC | Aug. 25, 2022 | COMPETITIVE GENERIC THERAPY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9 | WOMBAT-PK | CHEMBL | |||
| Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 9.70 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.81 | DRUG MATRIX | |||||
| Beta-3 adrenergic receptor | GPCR | Ki | 6.47 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.21 | CHEMBL | |||||
| Beta-2 adrenergic receptor | GPCR | Kd | 9.78 | CHEMBL | |||||
| Beta-1 adrenergic receptor | GPCR | Kd | 9.44 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019949 | VUID |
| N0000148034 | NUI |
| D00378 | KEGG_DRUG |
| 26921-17-5 | SECONDARY_CAS_RN |
| 4017930 | VANDF |
| 4019949 | VANDF |
| C0040233 | UMLSCUI |
| CHEBI:60787 | CHEBI |
| TIM | PDB_CHEM_ID |
| CHEMBL499 | ChEMBL_ID |
| DB00373 | DRUGBANK_ID |
| CHEMBL1200870 | ChEMBL_ID |
| D013999 | MESH_DESCRIPTOR_UI |
| 33624 | PUBCHEM_CID |
| 565 | IUPHAR_LIGAND_ID |
| 817W3C6175 | UNII |
| 10600 | RXNORM |
| 5585 | MMSL |
| 6436 | MMSL |
| d00139 | MMSL |
| 001856 | NDDF |
| 004741 | NDDF |
| 372880004 | SNOMEDCT_US |
| 75359005 | SNOMEDCT_US |
| 85591001 | SNOMEDCT_US |
| 91524-16-2 | SECONDARY_CAS_RN |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| COMBIGAN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0023-9211 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 26 sections |
| Timoptic in Ocudose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-1496 | SOLUTION | 6.80 mg | OPHTHALMIC | NDA | 20 sections |
| Timoptic in Ocudose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-1498 | SOLUTION | 3.40 mg | OPHTHALMIC | NDA | 20 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0055 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0221 | TABLET | 10 mg | ORAL | ANDA | 22 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0715 | TABLET | 20 mg | ORAL | ANDA | 22 sections |
| Dorzolamide Hydrochloride-Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0527-1763 | SOLUTION | 5 mg | OPHTHALMIC | ANDA | 25 sections |
| Brimonidine Tartrate and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-7186 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 23 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13811-618 | TABLET | 5 mg | ORAL | ANDA | 14 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13811-619 | TABLET | 10 mg | ORAL | ANDA | 14 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13811-620 | TABLET | 20 mg | ORAL | ANDA | 14 sections |
| DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE | Human Prescription Drug Label | 2 | 14445-405 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 24 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-189 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 25 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-288 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 23 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-288 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 23 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-289 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 23 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-289 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 23 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-365 | SOLUTION/ DROPS | 2.50 mg | OPHTHALMIC | ANDA | 22 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-366 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 22 sections |
| Dorzolamide HCl and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-514 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 28 sections |
| COSOPT PF | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-604 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 26 sections |
| COSOPT PF | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-604 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 26 sections |
| COSOPT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 17478-605 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 28 sections |
| Istalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-004 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 24 sections |
| Istalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-004 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | NDA | 24 sections |
| Dorzolamide Hydrochloride and Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-486 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 25 sections |
| Timolol Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-496 | SOLUTION | 6.80 mg | OPHTHALMIC | NDA authorized generic | 12 sections |
| Timoptic in Ocudose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-498 | SOLUTION | 3.40 mg | OPHTHALMIC | NDA | 12 sections |
| Timoptic in Ocudose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-499 | SOLUTION | 6.80 mg | OPHTHALMIC | NDA | 12 sections |
| Timoptic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-812 | SOLUTION | 2.50 mg | OPHTHALMIC | NDA | 24 sections |